Evaluation of 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one as a p38 MAPK inhibitor in MCF-7 and MDA-MB-231 breast cancer cell lines. AJPS [Internet]. 2025 Aug. 31 [cited 2026 Jun. 28];25(3):317-26. Available from: https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/1224